Mga Batayang Estadistika
| CIK | 1680581 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Fulcrum Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 28, 2025 |
August 2025 Disclaimer and Notice This presentation contains “forward-looking statements” of Fulcrum Therapeutics, Inc. |
|
| August 28, 2025 |
FORM 8-K Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commiss |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commissio |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM TH |
|
| July 29, 2025 |
Pociredir Pioneer Study: 12 mg Cohort Data Release July 29, 2025 Pociredir Pioneer Study: 12 mg Cohort Data Release July 29, 2025 Disclaimer and Notice This presentation contains “forward-looking statements” of Fulcrum Therapeutics, Inc. |
|
| July 29, 2025 |
Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 ― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious adverse events (SAEs) ― ― Observed robust and rapid pan-cellular increases in fetal |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commissio |
|
| May 7, 2025 |
(Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 01, 2025 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commission |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM T |
|
| May 1, 2025 |
Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025 ― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose cohort in early Q3 2025 and the 20 mg dose cohort by the end of 202 |
|
| April 30, 2025 |
(Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 4, 2025 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commi |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38978 FULCRUM THERAPE |
|
| February 25, 2025 |
As filed with the Securities and Exchange Commission on February 25, 2025 As filed with the Securities and Exchange Commission on February 25, 2025 Registration No. |
|
| February 25, 2025 |
Summary of Non-Employee Director Compensation Program. Exhibit 10.16 FULCRUM THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Effective January 24, 2025 The Company’s non-employee directors shall receive the following compensation for their service as members of the Board of Directors (the “Board”) of the Company. Director Compensation Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract |
|
| February 25, 2025 |
Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 ― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025, and the 20 mg dose cohort by the end of 2025 ― ― Ended 2024 with $241.0 million in cash, cash equivalents, and marketable securities; cash ru |
|
| February 25, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commi |
|
| February 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Fulcrum Therapeutics, Inc. |
|
| February 25, 2025 |
Insider Trading Policy of Registrant. Exhibit 19.1 FULCRUM THERAPEUTICS, INC. INSIDER TRADING POLICY 1. BACKGROUND AND PURPOSE 1.1 Why Have We Adopted This Policy? The federal securities laws prohibit any member of the Board of Directors (a “Director”), officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934 (the “Exchange Act”), an “executive officer”) or employee of Fulcrum Therapeutics, Inc. (together with it |
|
| February 12, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The unders |
|
| January 13, 2025 |
Exhibit 99.1 January 13, 2025 FULC FULCRUM THERAPEUTICS Disclaimer and Notice This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including express or implied statements regarding the development status of Fulcrum's product candidates, the potential advantages and therap |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commis |
|
| January 6, 2025 |
Exhibit B CONTROL PERSON IDENTIFICATION Suvretta Capital Management, LLC is the relevant entity for which Aaron Cowen is the control person. |
|
| January 6, 2025 |
Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G dated January 6, 2025 relating to the Common Stock, par value $0. |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commi |
|
| November 14, 2024 |
FULC / Fulcrum Therapeutics, Inc. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d1152793613g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 359616109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| November 14, 2024 |
SC 13G/A 1 p24-3193sc13ga.htm FULCRUM THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 359616109 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this stat |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCR |
|
| November 13, 2024 |
Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024 ― Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ― ― Conference call an |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commi |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commi |
|
| September 24, 2024 |
Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2024 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Comm |
|
| September 20, 2024 |
EX-99.1 2 d871955dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that |
|
| September 20, 2024 |
FULC / Fulcrum Therapeutics, Inc. / TCG Crossover GP II, LLC - SC 13G Passive Investment SC 13G 1 d871955dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 359616109 (CUSIP Number) September 12, 2024 (Date of Event Which Requires Filing of This Statement) Check |
|
| September 16, 2024 |
FULC / Fulcrum Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2424198d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 359616109 (CUSIP Number) September 12, 2024 (Date of Event Which Requires Filing of this State |
|
| September 12, 2024 |
Exhibit 99.1 Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) — Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 — — Fulcrum to suspend future losmapimod development — — Robust cash position enables Fulcrum to conti |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Comm |
|
| August 23, 2024 |
Exhibit 1: Joint Filing Agreement EX-1 2 tm2422355d2ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of August 23, 2024 is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a st |
|
| August 23, 2024 |
FULC / Fulcrum Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 359616109 (CUSIP Number) August 21, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2024 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commiss |
|
| August 22, 2024 |
EX-4.1 Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [●] (subject to adjustment) Warrant No. [●] Original Issue Date: [●], 2024 Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●] or its registered assigns (the “Holder”), is ent |
|
| July 31, 2024 |
Third Amendment to 2022 Inducement Stock Incentive Plan, effective as of June 17, 2024. Exhibit 10.2 THIRD AMENDMENT TO FULCRUM THERAPEUTICS, INC. 2022 INDUCEMENT STOCK INCENTIVE PLAN A. The Fulcrum Therapeutics, Inc. 2022 Inducement Stock Incentive Plan, as amended (the “Plan”) is hereby amended by deleting the first sentence of Section 4(a) and substituting therefore the following: “Subject to adjustment under Section 9, Awards may be made under the Plan for up to 6,150,000 shares |
|
| July 31, 2024 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Collaboration and License Agreement By and Between Fulcrum Therapeutics Inc. and Genzyme Corporation Dated May 11, 2024 TABLE OF CONTENTS Page Article 1 DEFINITIONS 1 Article 2 LICENSES 26 2.1 L |
|
| July 31, 2024 |
As filed with the Securities and Exchange Commission on July 31, 2024 S-8 As filed with the Securities and Exchange Commission on July 31, 2024 Registration No. |
|
| July 31, 2024 |
Exhibit 10.3 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL AMENDMENT No. 2 This Amendment No. 2 (this “Amendment No. 2”) is effective as of the date signed by the last party to sign below (the “Amendment No. 2 Effective Date”) and is made and entered in |
|
| July 31, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Fulcrum Therapeutics, Inc. |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commissio |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM TH |
|
| July 31, 2024 |
Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) by the end of October 2024 ― ― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commissio |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM T |
|
| May 13, 2024 |
Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024 ― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2024 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commission |
|
| May 13, 2024 |
Employment Agreement, dated March 18, 2024, by and between the Registrant and Patrick Horn. Exhibit 10.1 FULCRUM THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made as of March 18, 2024 (the “Effective Date”) by and between Fulcrum Therapeutics, Inc. (the “Company”) and Patrick Horn (the “Executive”) (the Company and the Executive each a “Party” and together the “Parties”). RECITALS WHEREAS, the Company desires to employ the Exe |
|
| April 24, 2024 |
FULCRUM THERAPEUTICS, INC. 26 Landsdowne Street Cambridge, MA 02139 FULCRUM THERAPEUTICS, INC. 26 Landsdowne Street Cambridge, MA 02139 VIA EDGAR April 24, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Fulcrum Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 Filed February 27, 2024 File No. 333-277419 Ladies and Gentlemen: Pursuant to Rule 461 under th |
|
| April 19, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| February 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commi |
|
| February 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Fulcrum Therapeutics, Inc. |
|
| February 27, 2024 |
Form of Subordinated Indenture Exhibit 4.2 FULCRUM THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’ |
|
| February 27, 2024 |
As filed with the Securities and Exchange Commission on February 27, 2024 As filed with the Securities and Exchange Commission on February 27, 2024 Registration No. |
|
| February 27, 2024 |
As filed with the Securities and Exchange Commission on February 27, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 27, 2024 Registration No. |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38978 FULCRUM THERAPE |
|
| February 27, 2024 |
Exhibit 4.1 FULCRUM THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certifi |
|
| February 27, 2024 |
Exhibit 1.2 Fulcrum Therapeutics, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement February 27, 2024 Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 Stifel, Nicolaus & Company, Incorporated 787 7th Avenue, 11th Floor New York, New York 10019 Ladies and Gentlemen: Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”) |
|
| February 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Fulcrum Therapeutics, Inc. |
|
| February 27, 2024 |
Exhibit 21.1 List of Subsidiaries Jurisdiction of Incorporation Fulcrum Therapeutics Securities Corp. Massachusetts |
|
| February 27, 2024 |
Second Amendment to 2022 Inducement Stock Incentive Plan. Exhibit 10.12 SECOND AMENDMENT TO FULCRUM THERAPEUTICS, INC. 2022 INDUCEMENT STOCK INCENTIVE PLAN A. The Fulcrum Therapeutics, Inc. 2022 Inducement Stock Incentive Plan (as amended by the First Amendment to the Fulcrum Therapeutics, Inc. 2022 Inducement Stock Incentive Plan and as amended from time to time, the “Plan”) is hereby amended by deleting the first sentence of Section 4(a) and substituti |
|
| February 27, 2024 |
Compensation Recovery Policy of Registrant. Exhibit 97.1 FULCRUM THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY Adopted as of November 16, 2023 Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered P |
|
| February 27, 2024 |
Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023 ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Restart of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) underway ― ― Conference call and w |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 359616109 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pur |
|
| February 14, 2024 |
Exhibit 1: Joint filing agreement EX-1 2 tm246065d9ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a |
|
| February 14, 2024 |
FULC / Fulcrum Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246065d9sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* FULCRUM THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 359616109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stateme |
|
| February 14, 2024 |
FULC / Fulcrum Therapeutics, Inc. / Third Rock Ventures III, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Fulcrum Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 359616109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 13, 2024 |
FULC / Fulcrum Therapeutics, Inc. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d1096315613g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 359616109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| February 7, 2024 |
SC 13G/A 1 p24-0425sc13ga.htm FULCRUM THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 359616109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This State |
|
| November 7, 2023 |
Exhibit 10.2 FULCRUM THERAPEUTICS, INC. EXECUTIVEEMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made as of August 7, 2023 (the “Effective Date”) by and between Fulcrum Therapeutics, Inc. (the “Company”) and Alan Musso (the “Executive”) (the Company and the Executive each a “Party” and together the “Parties”). RECITALS WHEREAS, the Company desires to employ the Execut |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commi |
|
| November 7, 2023 |
Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023 ― Completed enrollment in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD); expect to report topline data in the fourth quarter of 2024 ― ― U.S. Food and Drug Administration (FDA) lifted clinical hold for pociredir (formerly FTX-6058) in sickle c |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCR |
|
| November 7, 2023 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL LICENSE AGREEMENT between CAMP4 THERAPEUTICS CORP. and FULCRUM THERAPEUTICS INC. LICENSE AGREEMENT This License Agreement (“Agreement”) is entered into as of July 5th, 2023 (the “Effective Date” |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Comm |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commiss |
|
| August 22, 2023 |
EX-99.1 Exhibit 99.1 FTX-6058 f o r S i c k l e C e l l D i s e a s e Program Update F U L C R U M T H E R A P E U T I C S Disclaimer and Notice This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in th |
|
| August 3, 2023 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL AMENDMENT This Amendment (this “Amendment”) is effective as of the date signed by the last party to sign below (the “Amendment Effective Date”) and is made and entered into by and among Fulcrum |
|
| August 3, 2023 |
Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023 ― Screening closed for the Phase 3 REACH pivotal trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) ― ― Expect to report topline data for REACH in the fourth quarter of 2024 ― ― Interactions continue with the U.S. Food and Drug Administration (FDA) to resolve clini |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 02, 2023 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commiss |
|
| August 3, 2023 |
Exhibit 10.2 FULCRUM THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made as of May 12, 2023 (the “Effective Date”) by and between Fulcrum Therapeutics, Inc. (the “Company”) and Alex Sapir (the “Executive”) (the Company and the Executive each a “Party” and together the “Parties”). RECITALS WHEREAS, the Company desires to employ the Executi |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM TH |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2023 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commission |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-389 |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-389 |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-389 |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commission |
|
| June 9, 2023 |
EX-3.1 Exhibit 3.1 Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HERE BY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “FULCRUM THERAPEUTICS, INC.”, FILED IN THIS OFFICE ON THE EIGHTH DAY OF JUNE, A.D. 2023, AT 12:29 O`CLOCK P.M. 5794667 8100 Authentication: 203511925 SR# 20232703439 Date: 06-08-23 You ma |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2023 |
Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023 ― Appointed Alex C. Sapir CEO & President, effective July 1st, 2023 ― ― On track to complete enrollment in Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) during 2H’23 ― ― Active discussions continue with the U.S. Food and Drug Administration (F |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM T |
|
| May 15, 2023 |
Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Agreement”), entered into as of April 22, 2023, (the “Effective Date”), by and between Esther Rajavelu (the “Consultant”) and Fulcrum Therapeutics, Inc., a company located at 26 Landsdowne Street Cambridge, MA 02139 (hereinafter “Company”). WHEREAS, Company desires to retain the services of Consultant as an independent consultant w |
|
| April 28, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 28, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 18, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commissi |
|
| March 9, 2023 |
Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022 ― Company is working to address clinical hold on the Investigational New Drug application for FTX-6058 for the potential treatment of sickle cell disease ― ― FTX-6058 data from 12 mg cohort of Phase 1b trial show clinically relevant fetal hemoglobin increases of up |
|
| March 9, 2023 |
Exhibit 10.18 January 3, 2023 Robert J. Gould Dear Robert: Fulcrum Therapeutics, Inc. (the “Company”) is pleased to extend you a consulting role as Interim Chief Executive Officer of the Company (“Interim CEO”), reporting to the Board of Directors of the Company (the “Board”), effective January 3, 2023 (the “Effective Date”). The terms are as follows: 1. Term. It is anticipated that your consultin |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38978 FULCRUM THERAPE |
|
| March 9, 2023 |
DocuSign Envelope ID: 941E6C11-A720-4450-BEC2-6BF3A624C190 Exhibit 10.19 SEVERANCE AGREEMENT This Severance Agreement (this “Agreement”) is made between Fulcrum Therapeutics, Inc. (the “Company”) and Bryan Stuart (the “Executive”). The Company together with the Executive shall be referred to as the “Parties”. WHEREAS, the Parties entered into an Employment Agreement dated March 31, 2021 (the “Empl |
|
| March 9, 2023 |
Exhibit 10.13 FIRST AMENDMENT TO FULCRUM THERAPEUTICS, INC. 2022 INDUCEMENT STOCK INCENTIVE PLAN A. The Fulcrum Therapeutics, Inc. 2022 Inducement Stock Incentive Plan (the “Plan”) is hereby amended by deleting the first sentence of Section 4(a) and substituting therefore the following: “Subject to adjustment under Section 9, Awards may be made under the Plan for up to 3,750,000 shares of common s |
|
| March 9, 2023 |
Employment Agreement, dated November 7, 2022, by and between the Registrant and Santiago Arroyo. Exhibit 10.24 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of November 7, 2022 (Executive’s first day of employment, after all eligibility criteria have been met) by and between Fulcrum Therapeutics, Inc. (the “Company”), and Santiago Arroyo (the “Executive”) (together, the “Parties”). RECITALS WHEREAS, the Company desires to employ the Executive as its Chief Medical |
|
| March 9, 2023 |
Power of Attorney (included on signature page) S-8 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. |
|
| March 9, 2023 |
Separation Agreement, dated October 14, 2022, by and between the Registrant and Judith Dunn. Exhibit 10.21 October 14, 2022 Ms. Judith Dunn Dear Judith: This letter confirms that your Employment Agreement dated March 19, 2021 between you and Fulcrum Therapeutics, Inc. (the "Company") is terminating effective on the Separation Date (as defined below), and summarizes the terms of the separation agreement that the Company is willing to offer as a result of your separation from the Company. P |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 09, 2023 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commissi |
|
| March 9, 2023 |
Exhibit 10.16 FULCRUM THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Effective February 3, 2023 The Company’s non-employee directors shall receive the following compensation for their service as members of the Board of Directors (the “Board”) of the Company. Director Compensation Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract |
|
| March 9, 2023 |
Exhibit 21.1 List of Subsidiaries Jurisdiction of Incorporation Fulcrum Therapeutics Securities Corp. Massachusetts |
|
| March 9, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Fulcrum Therapeutics, Inc. |
|
| March 6, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 359616109 (CUSIP Number) February 24, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2023 |
SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #1 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Fulcrum Therapeutics, Inc. (Titl |
|
| February 14, 2023 |
FULC / Fulcrum Therapeutics Inc / Third Rock Ventures III, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d442890dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Fulcrum Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 359616109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) |
|
| February 14, 2023 |
SC 13G/A 1 p23-0510sc13ga.htm FULCRUM THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 359616109 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this state |
|
| February 13, 2023 |
FULC / Fulcrum Therapeutics Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d992860913g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 359616109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 9, 2023 |
SC 13G/A 1 p23-0716sc13ga.htm FULCRUM THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 359616109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This State |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Fulcrum Therapeutics Inc. (Name of Issuer) common stock (Title of Class of Securities) 359616109 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| January 18, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260754 PROSPECTUS SUPPLEMENT (To Prospectus dated April 28, 2022) 9,615,384 Shares Common Stock We are offering 9,615,384 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “FULC”. The last reported sale price of our common stock on The Nasdaq Global Market on January 17, 2023 w |
|
| January 18, 2023 |
EX-1.1 2 d451832dex11.htm EX-1.1 Exhibit 1.1 Execution Version Fulcrum Therapeutics, Inc. Common Stock, par value $0.001 per share Underwriting Agreement January 17, 2023 Goldman Sachs & Co. LLC SVB Securities LLC Piper Sandler & Co. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street, New York, New York 102 |
|
| January 18, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2023 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commis |
|
| January 18, 2023 |
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock Exhibit 99.1 Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock CAMBRIDGE, Mass. – January 17, 2023 – Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the pricing of an underwritten public offering of 9,615,384 shares of its common |
|
| January 17, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2023 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commis |
|
| January 17, 2023 |
Subject to Completion, dated January 17, 2023 424B5 1 d405392d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260754 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement has been filed with the Securities and Exchange Commission and is effective. This prospectus supplement is not an offer to sell these securities and it is not soliciting |
|
| January 17, 2023 |
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock Exhibit 99.1 Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass. – January 17, 2023 – Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its co |
|
| January 6, 2023 |
FULC / Fulcrum Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* FULCRUM THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 359616109 (CUSIP Number) January 4, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2023 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commiss |
|
| January 4, 2023 |
Fast Track Designation Granted in December 2022 EX-99.2 Pipeline and Catalysts Wholly Owned Clinical Programs FSHD Losmapimod (DUX4 Inhibitor) Complete Phase 3 enrollment in 2H'23 SCD FTX-6058 (Oral HbF Inducer) Phase 1b data update in 4Q'23 Wholly Owned Discovery Programs Blood Disorder Neurologic Disorder IND expected in 2023* Muscle Disorder IND expected in 2023* Collaborations Cardiomyopathies Indication MOA Preclinical Phase 1 Phase 2 Phas |
|
| January 4, 2023 |
EX-99.1 Exhibit 99.1 Fulcrum Therapeutics Provides Business Update and 2023 Outlook — FTX-6058 granted Fast Track Designation for sickle cell disease (SCD) from FDA in December 2022 — — Completed enrollment in 6 mg and 2 mg dose cohorts of the Phase 1b trial of FTX-6058 in SCD; enrollment ongoing in 12 mg dose cohort — — Additional FTX-6058 data from 6 mg cohort of ongoing Phase 1b trial show clin |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2022 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commi |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. |
|
| November 8, 2022 |
Exhibit 99.1 Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results – Selected 12mg as the dose for next cohort in the Phase 1b trial of FTX-6058 in sickle cell disease (SCD) – – Presented 96-week data from the Phase 2 ReDUX4 trial open label extension (OLE) study at World Muscle Society (WMS) conference – – Completed equity raise of approximately $80.8 |
|
| October 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2022 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commis |
|
| August 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* FULCRUM THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 359616109 (CUSIP Number) August 16, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| August 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commiss |
|
| August 17, 2022 |
Exhibit 1.1 Fulcrum Therapeutics, Inc. Common Stock, par value $0.001 per share Underwriting Agreement August 15, 2022 Goldman Sachs & Co. LLC, SVB Securities LLC As representatives (the ?Representatives?) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282-2198 c/o SVB Securities LLC 53 State Street, 40th Floor Boston, MA |
|
| August 17, 2022 |
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock Exhibit 99.1 Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass. ? August 15, 2022 ? Fulcrum Therapeutics, Inc.? (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common |
|
| August 17, 2022 |
Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass. ? August 15, 2022 ? Fulcrum Therapeutics, Inc.? (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the pricing of an underwritten public offering of 9,590,792 shares of its common stock at |
|
| August 17, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260754 PROSPECTUS SUPPLEMENT (To Prospectus dated April 28, 2022) 9,590,792 Shares Common Stock We are offering 9,590,792 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol ?FULC?. The last reported sale price of our common stock on The Nasdaq Global Market on August 15, 2022 wa |
|
| August 17, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commiss |
|
| August 15, 2022 |
Subject to Completion, dated August 15, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260754 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement has been filed with the Securities and Exchange Commission and is effective. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commiss |
|
| August 11, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of September 7, 2021 (Executive?s first day of employment, after all eligibility criteria have been met) by and between Fulcrum Therapeutics, Inc. (the ?Company?), and Mel Hayes (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS, the Company desires to employ the Executive as its Chief Commercial O |
|
| August 11, 2022 |
Exhibit 99.1 Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update ? Presented initial data from Phase 1b trial in sickle cell disease (SCD), which demonstrate rapid and robust increases in hemoglobin F (HbF); supports proof-of-concept that FTX-6058 is a novel oral HbF inducer ? ? Announced enrollment of first patient in Phase 3 REACH trial of losmapimod in facio |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commiss |
|
| July 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2022 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commission |
|
| June 22, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| June 22, 2022 |
FULC / Fulcrum Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Fulcrum Therapeutics, Inc. (Title of Class of Securities) Common Stock, $0.001 Par Valu |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commissio |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 6, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 10, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commission File |
|
| May 10, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260754 PROSPECTUS SUPPLEMENT (To prospectus dated April 28, 2022) $50,000,000 Common Stock We have entered into an equity distribution agreement with Piper Sandler & Co., or Piper Sandler, dated May 9, 2022, relating to the sale of shares of our common stock offered by this prospectus supplement. In accordance with the terms o |
|
| May 10, 2022 |
Exhibit 1.1 FULCRUM THERAPEUTICS, INC. Common Stock EQUITY DISTRIBUTION AGREEMENT May 9, 2022 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this ?Agreement?), Fulcrum Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell from time to time through Piper Sandler & C |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. |
|
| May 9, 2022 |
Exhibit 99.1 Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results ? Initial data from Phase 1b trial of FTX-6058 in sickle cell disease to be presented at the EHA 2022 Congress ? ? Phase 3 REACH trial of losmapimod in FSHD expected to begin in 2Q 2022 ? ? Conference call scheduled for 8:00 a.m. ET today ? CAMBRIDGE, Mass. ? May 9, 2022 ? Fulcrum Therapeu |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2022 Fulcrum Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38978 47-4839948 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2022 |
As filed with the Securities and Exchange Commission on May 9, 2022 POS EX 1 d268123dposex.htm POS EX As filed with the Securities and Exchange Commission on May 9, 2022 Registration No. 333-260754 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-48399 |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2022 |
DEF 14A 1 d53754ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use |
|
| March 10, 2022 |
SC 13G 1 p22-1064sc13g.htm FULCRUM THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 359616109 (CUSIP Number) February 28, 2022 (Date of Event Which Requires Filing of This Statement) |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2022 Fulcrum Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38978 47-4839948 (State or other jurisdiction of incorporation) (Commissio |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Fulcrum Therapeutics Inc. (Name of Issuer) common stock (Title of Class of Securities) 359616109 (CUSIP Number) March 04, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| March 3, 2022 |
Exhibit 10.23 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of January 3rd, 2022, ( Executive?s first day of employment, after all eligibility criteria have been met) by and between Fulcrum Therapeutics, Inc. (the ?Company?), and Esther Rajavelu (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS, the Company desires to employ the Executive as its Chief Fin |
|
| March 3, 2022 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Fulcrum Therapeutics, Inc. |
|
| March 3, 2022 |
Exhibit 10.13 FULCRUM THERAPEUTICS, INC. NONSTATUTORY STOCK OPTION AGREEMENT Granted Under 2022 Inducement Stock Incentive Plan Fulcrum Therapeutics, Inc. (the ?Company?) hereby grants the following stock option pursuant to its 2022 Inducement Stock Incentive Plan (the ?Plan?). The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the ?Participant?): Gr |
|
| March 3, 2022 |
Exhibit 21.1 List of Subsidiaries Jurisdiction of Incorporation Fulcrum Therapeutics Securities Corp. Massachusetts |
|
| March 3, 2022 |
As filed with the Securities and Exchange Commission on March 3, 2022 POS AM 1 d308362dposam.htm POS AM Table of Contents As filed with the Securities and Exchange Commission on March 3, 2022 Registration No. 333-260754 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charte |
|
| March 3, 2022 |
Exhibit 99.1 Fulcrum Therapeutics? Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results ? Clear path forward for Phase 3 REACH trial with losmapimod in FSHD; Trial expected to begin in 2Q 2022 ? ? On track to report initial data from Phase 1b trial with FTX-6058 in sickle cell disease in 2Q 2022 ? ? Conference call scheduled for 8:00 a.m. ET today ? CAMBRIDGE, |
|
| March 3, 2022 |
Exhibit 10.15 FULCRUM THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Effective January 19, 2022 The Company?s non-employee directors shall receive the following compensation for their service as members of the Board of Directors (the ?Board?) of the Company. Director Compensation Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract |
|
| March 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2022 Fulcrum Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38978 47-4839948 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38978 FULCRUM THERAPE |
|
| March 3, 2022 |
As filed with the Securities and Exchange Commission on March 2, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 2, 2022 Registration No. |
|
| March 3, 2022 |
Exhibit 10.14 Fulcrum Therapeutics, Inc. Restricted Stock Unit Agreement Granted under 2022 Inducement Stock Incentive Plan Fulcrum Therapeutics, Inc. (the ?Company?) hereby grants the following restricted stock units pursuant to its 2022 Inducement Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the ?Participant?): Grant Da |
|
| March 3, 2022 |
As filed with the Securities and Exchange Commission on March 3, 2022 As filed with the Securities and Exchange Commission on March 3, 2022 Registration No. |
|
| March 3, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment to Form S-3 (Form Type) Fulcrum Therapeutics, Inc. |
|
| March 3, 2022 |
Exhibit 10.10 Fulcrum Therapeutics, Inc. Restricted Stock Unit Agreement Fulcrum Therapeutics, Inc. (the ?Company?) hereby grants the following restricted stock units pursuant to its 2019 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the ?Participant?): Grant Date: Number of restricted stock units (?RSUs?) granted: Number, |
|
| March 3, 2022 |
Exhibit 10.12 FULCRUM THERAPEUTICS, INC. 2022 INDUCEMENT STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2022 Inducement Stock Incentive Plan (the ?Plan?) of Fulcrum Therapeutics, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important co |
|
| February 14, 2022 |
FULC / Fulcrum Therapeutics Inc / Third Rock Ventures III, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Fulcrum Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 359616109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2022 |
EXHIBIT 24 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Kevin Gillis his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirec |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 359616109 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pur |
|
| February 14, 2022 |
EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| February 11, 2022 |
FULC / Fulcrum Therapeutics Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 27, 2022 |
As filed with the Securities and Exchange Commission on January 26, 2022 As filed with the Securities and Exchange Commission on January 26, 2022 Registration No. |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2022 Fulcrum Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38978 47-4839948 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 10, 2022 |
Exhibit 99.1 Fulcrum Therapeutics? Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases First patient dosed in Phase 1b trial of FTX-6058 in sickle cell disease; Initial data expected in 2Q 2022 Submitted IND for FTX-6058 to support initiation of Phase 1b trial in select hemoglobinopathies in 2Q 2022 On track to provide update on losmapimod in FS |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2022 Fulcrum Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38978 47-4839948 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 4, 2022 |
Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer Exhibit 99.1 Fulcrum Therapeutics? Appoints Esther Rajavelu as Chief Financial Officer CAMBRIDGE, Mass., January 4, 2022 ? Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Esther Rajavelu as Chief Financial Officer. Ms. Rajavelu brings nearly 20 |
|
| December 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 6, 2021 Fulcrum Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38978 47-4839948 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 16, 2021 Fulcrum Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38978 47-4839948 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 17, 2021 |
Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors EX-99.1 2 d189896dex991.htm EX-99.1 Exhibit 99.1 Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors CAMBRIDGE, Mass., November 17, 2021 – Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Sonja L. Banks to the company’s board |
|
| November 4, 2021 |
Exhibit 10.1 FULCRUM THERAPEUTICS, INC. NONSTATUTORY STOCK OPTION AGREEMENT Fulcrum Therapeutics, Inc. (the ?Company?) hereby grants the following stock option. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the ?Participant?): Grant Date: Number of shares of the Company?s Common Stock subject to this option (?Shares?): Option exercise price per |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. |
|
| November 4, 2021 |
Exhibit 1.3 FULCRUM THERAPEUTICS, INC. AMENDMENT NO. 1 TO THE EQUITY DISTRIBUTION AGREEMENT November 4, 2021 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Reference is made to the Equity Distribution Agreement, dated August 11, 2020 (the ?Equity Distribution Agreement?), between Fulcrum Therapeutics, Inc., a Delaware corporation (the ? |
|
| November 4, 2021 |
Form of Subordinated Indenture Exhibit 4.5 FULCRUM THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314 |
|
| November 4, 2021 |
Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| November 4, 2021 |
As filed with the Securities and Exchange Commission on November 4, 2021 Table of Contents As filed with the Securities and Exchange Commission on November 4, 2021 Registration No. |
|
| November 4, 2021 |
Exhibit 4.4 FULCRUM THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) In |
|
| November 4, 2021 |
Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| November 4, 2021 |
Exhibit 99.1 Fulcrum Therapeutics? Reports Recent Business Highlights and Third Quarter 2021 Financial Results ? On-track to initiate enrollment by year-end in Phase 1b clinical trial of FTX-6058 in people with sickle cell disease ? ? Losmapimod update planned for Q1 2022 ? ? Raised $144.2 million in gross proceeds from August 2021 public offering, extending cash runway into 2024 ? ? Conference ca |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2021 Fulcrum Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38978 47-4839948 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 27, 2021 |
FULC / Fulcrum Therapeutics Inc / GLAXOSMITHKLINE PLC - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1- Exit Filing)* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 359616109 (CUSIP Number) August 16, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| August 12, 2021 |
Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock Exhibit 99.1 Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock CAMBRIDGE, Mass., August 11, 2021 ? Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 6,600,000 shares of its c |
|
| August 12, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2021 Fulcrum Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38978 47-4839948 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 12, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-244136 Registration No. 333-258740 PROSPECTUS SUPPLEMENT (to Prospectus dated August 17, 2020) 6,600,000 Shares Common Stock We are offering 6,600,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Global Market under the symbol ?FULC.? The last reported sales price of our common stock on |
|
| August 12, 2021 |
Exhibit 1.1 6,600,000 Shares FULCRUM THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT August 11, 2021 August 11, 2021 SVB Leerink LLC Piper Sandler & Co. Stifel, Nicolaus & Company, Incorporated As Representatives of the several underwriters c/o SVB Leerink LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o Piper Sandler & Co. 1251 Avenue of the Ameri |
|
| August 11, 2021 |
As filed with the Securities and Exchange Commission on August 11, 2021 As filed with the Securities and Exchange Commission on August 11, 2021 Registration No. |
|
| August 11, 2021 |
SUBJECT TO COMPLETION, DATED AUGUST 10, 2021 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-244136 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement has been filed with the Securities and Exchange Commission and is effective. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities |
|
| August 10, 2021 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of May 10, 2021 ( Executive?s first day of employment, after all eligibility criteria have been met) by and between Fulcrum Therapeutics, Inc. (the ?Company?), and Christopher Morabito (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS, the Company desires to employ the Executive as its Chief Medic |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2021 Fulcrum Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38978 47-4839948 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. |
|
| August 10, 2021 |
FULC / Fulcrum Therapeutics Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 10, 2021 |
Exhibit 99.1 Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results – Reported positive interim results from ongoing Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease demonstrating proof of mechanism and proof of biology – – Company plans to initiate enrollment in a Phase 1b clinical trial in sickle cell patients in 4Q 2021 – |
|
| June 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2021 Fulcrum Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38978 47-4839948 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 11, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2021 Fulcrum Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38978 47-4839948 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 6, 2021 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of February 6, 2021 (the ?Effective Date?) by and between Fulcrum Therapeutics, Inc. (the ?Company?), and Christopher Moxham (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS, the Company desires to continue to employ the Executive as its Chief Scientific Officer; and WHEREAS, the Company and the |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2021 Fulcrum Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38978 47-4839948 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 6, 2021 |
EX-10.2 3 fulc-ex10257.htm EX-10.2 Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”), is made as of 19 March 2021 by and between Fulcrum Therapeutics, Inc. (the “Company”), and Judith Dunn (the “Executive”) (together, the “Parties”). RECITALS WHEREAS, the Company desires to continue to employ the Executive as its President, Research and Development; and WHEREAS, the Com |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. |
|
| May 6, 2021 |
EX-10.3 4 fulc-ex10358.htm EX-10.3 Exhibit 10.3 FULCRUM THERAPEUTICS, INC. CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”), made this 31st day of March, 2021, is entered into by Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), and Robert J. Gould, an individual residing at [**] (the “Consultant”). WHEREAS, the Company desires to retain the services of the Consul |
|
| May 6, 2021 |
Exhibit 99.1 Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results ? On track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) at virtual FSHD International Research Congress in June 2021 ? ? On track to report data from Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disea |
|
| May 6, 2021 |
Exhibit 10.4 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of March 31, 2021 by and between Fulcrum Therapeutics, Inc. (the ?Company?), and Bryan Stuart (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS, the Company desires to continue to employ the Executive as its President and Chief Executive Officer; and WHEREAS, the Company and the Executive are part |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 24, 2021 |
Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development Exhibit 99.1 Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development CAMBRIDGE, Mass., March 24, 2021 ? Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Judith A. Dunn, Ph.D. has been appointed President of Research and De |
|
| March 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2021 Fulcrum Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38978 47-4839948 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 4, 2021 |
Exhibit 10.16 DocuSign Envelope ID: D84DAD84-6F6A-4E22-B758-E6A7CB2A970D EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?), is made as of October 29, 2020 (the ?Effective Date?) by and between Fulcrum Therapeutics, Inc. (the ?Company?), and Curtis Oltmans (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS, the Company desires to continue to employ the Executive as its Sen |
|
| March 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38978 FULCRUM THERAPE |
|
| March 4, 2021 |
Exhibit 21.1 List of Subsidiaries Jurisdiction of Incorporation Fulcrum Therapeutics Securities Corp. Massachusetts |
|
| March 4, 2021 |
EX-99.1 Exhibit 99.1 Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results – Company on track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in late-2Q 2021 – – On track to report results from Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease in mid-2 |
|
| March 4, 2021 |
Power of Attorney (included on the signature pages of this registration statement) As filed with the Securities and Exchange Commission on March 4, 2021 Registration No. |
|
| March 4, 2021 |
8-K 1 d122679d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2021 Fulcrum Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38978 47-4839948 (State or Other Jurisdiction of |
|
| March 4, 2021 |
Summary of Non-Employee Director Compensation Program. Exhibit 10.9 FULCRUM THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Effective January 25, 2021 The Company?s non-employee directors shall receive the following compensation for their service as members of the Board of Directors (the ?Board?) of the Company. Director Compensation Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract |
|
| March 4, 2021 |
EX-99.2 3 d122679dex992.htm EX-99.2 Exhibit 99.2 Fulcrum Therapeutics Announces CEO Transition – Robert J. Gould, Ph.D. announces retirement; will continue to serve as board member and advisor – – Bryan E. Stuart promoted to president and chief executive officer effective March 31, 2021 – CAMBRIDGE, Mass., March 4, 2021 – Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutica |
|
| February 16, 2021 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Fulcrum Therapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value $0. |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* Fulcrum Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 359616109 (CUSIP Number) December 31, 2020 (Date o |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 20, 2021 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-244136 PROSPECTUS SUPPLEMENT (to Prospectus dated August 17, 2020) 4,000,000 Shares Common Stock We are offering 4,000,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Global Market under the symbol “FULC.” The last reported sales price of our common stock on the Nasdaq Global Mar |
|
| January 20, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 19, 2021 Fulcrum Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38978 47-4839948 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 20, 2021 |
EX-1.1 Exhibit 1.1 EXECUTION VERSION 4,000,000 Shares FULCRUM THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT January 19, 2021 January 19, 2021 SVB Leerink LLC Piper Sandler & Co. Credit Suisse Securities (USA) LLC As Representatives of the several underwriters c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/o Piper Sandler & Co. |
|
| January 20, 2021 |
Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock EX-99.1 Exhibit 99.1 Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Massachusetts, January 19, 2021 – Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 4,000,000 shares of i |
